SCHEMBL5657415

SCHEMBL5657415

Cc1ccc(C(=O)NCc2ccc(NC3=NCCN3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 5/20 0.59
ADRA2B P18089 5/20 0.59
ADRA2C P18825 5/20 0.59
PTGIR P43119 4/20 0.55
HTT P42858 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
WDR5 P61964 3/20 0.53
NAMPT P43490 1/20 0.51
MLLT1 Q03111 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
MMP2 P08253 1/20 0.49
CYP3A4 P08684 1/20 0.49
STAT3 P40763 1/20 0.49
MMP13 P45452 1/20 0.49
MAPK14 Q16539 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655906 0.97 ADRA2A (0.55) ADRA2AADRA2BADRA2CPTGIRHTT
SCHEMBL5658627 0.91 ADRA2A (0.59) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5658659 0.91 ADRA2A (0.63) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5657241 0.89 ADRA2A (0.60) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5656497 0.89 KDM4E (0.57) ADRA2AADRA2BADRA2CPTGIRHTT
SCHEMBL5659119 0.89 PTGIR (0.59) ADRA2AADRA2BADRA2CPTGIRNAMPT
SCHEMBL5656678 0.89 ADRA2A (0.56) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5656503 0.88 ADRA2A (0.59) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5659779 0.88 ADRA2A (0.59) ADRA2AADRA2BADRA2CPTGIRWDR5
SCHEMBL5657222 0.88 ADRA2A (0.59) ADRA2AADRA2BADRA2CPTGIRWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-6998414-B2 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC (US) 2006-02-14 US disclosed
US-20060004075-A1 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004075-A1 Substituted aryl amides as IP antagonists INSR, INSRR, GIPR ADRA2A 90/4885ADRA2B 82/4885ADRA2C 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.